Bayer: pediatric anticoagulant looks safe in phase III study
(CercleFinance.com) - Bayer's anticoagulant Xarelto has showed strong efficacy and safety profile in a phase III study in children with venous thromboembolism, a form of excessive blood clotting.
The trial showed that only 4 out of 335 (1.2%) children treated with Xarelto had recurrent recurrent venous thromboembolism, the German company said.
Current treatment of venous thromboembolism in children often relies on parenteral administration of anticoagulants and requires laboratory monitoring and dose adjustments, Bayer said.
The group said it plans to submit an application to the European Medicines Agency (EMA) for the extension of the Xarelto marketing authorization to make this new treatment option.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The trial showed that only 4 out of 335 (1.2%) children treated with Xarelto had recurrent recurrent venous thromboembolism, the German company said.
Current treatment of venous thromboembolism in children often relies on parenteral administration of anticoagulants and requires laboratory monitoring and dose adjustments, Bayer said.
The group said it plans to submit an application to the European Medicines Agency (EMA) for the extension of the Xarelto marketing authorization to make this new treatment option.
Copyright (c) 2019 CercleFinance.com. All rights reserved.